Scleroderma

Men with systemic sclerosis who smoke demonstrate a greater risk for death than women with SSc who smoke, according to a study published in RMD Open.

DESTIN, Fla. — Detection and treatment of interstitial lung disease in systemic sclerosis calls for early and aggressive action, according to data presented at the Congress of Clinical Rheumatology East.

DESTIN, Fla. — Stem cell transplantation, accompanied by total body radiation, is the only “cure” for progressive systemic sclerosis currently available, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.

Patients with systemic sclerosis who demonstrate left ventricular abnormalities, either overt or “subclinical,” have poorer survival and increased shortness of breath, according to data published in Seminars in Arthritis and Rheumatism.

May is Lupus Awareness Month, a time to raise awareness and educate the public on the physical, emotional and financial impact of lupus.

The 2022 European Society of Cardiology risk assessment tool, when applied at baseline and follow-up, can accurately predict survival in patients with systemic sclerosis-associated pulmonary arterial hypertension, according to data.

The FDA has granted orphan drug designation to BLR-200, an investigational therapy for the treatment of scleroderma, according to a press release from manufacturer.

Nearly three-quarters of patients with systemic sclerosis demonstrate symptom burden that met the threshold for needing specialist palliative care, according to data published in Arthritis Care & Research.

SCOTTSDALE, Ariz. — Chimeric antigen receptor T-cell therapy had “unprecedented” and “astonishing” results in lupus, but whether it will truly revolutionize rheumatology care remains to be seen, according to a speaker.

As much as 43% of patients with systemic sclerosis demonstrate evidence of myopathy, while those with proximal weakness and higher creatine kinase exhibit worse function and survival, according to data.